Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432533 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 283
- Enrollment target
NCT03432533 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 283 participants.
The verdict
NCT03432533, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 283 participants
- Enrollment target
Study Summary
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)
Interventions
- DRUG romosozumab HCP administration with PFS
- DEVICE romosozumab self-administration with AI/Pen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2020-01-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03432533
The ClinicalTrials.gov registry entry for NCT03432533 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which romosozumab HCP administration with PFS is the first listed.
NCT03432533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03432533 about?
NCT03432533 is a clinical study titled "A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis". To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration wit...
What is the current status of trial NCT03432533?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 283 participants. The study started on 2018-02-06. Estimated completion is 2020-01-08.
What interventions are being tested in trial NCT03432533?
The interventions under investigation include: romosozumab HCP administration with PFS (DRUG), romosozumab self-administration with AI/Pen (DEVICE).
Who is sponsoring clinical trial NCT03432533?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.